Scholarlink

Purpose <p>Image-guided energy-based tumour ablation (IGTA) with radiofrequency ablation (RFA), microwave ablation (MWA) and cryotherapy are curative local therapies for T1 renal cell carcinoma (RCC). The aim of this study is to evaluate the oncological outcomes and survival after IGTA of T1 RCC in our unit over a 10-year period.</p> Methods <p>We retrospectively reviewed all patients with biopsy proven RCC who underwent IGTA of a T1 tumour between 1st March 2013 and 1st June 2023. Data collected included: patient demographics, tumour size and histology, pre and post procedure creatinine, ablation technique, complications, efficacy, disease free survival and overall survival (OS).</p> Results <p>Fifty IGTAs were performed on 46 RCC (mean diameter 2.6&#xa0;cm) in 45&#xa0;patients. Complications occurred in 8% of procedures (<i>n</i> = 4/50). Median clinical follow- up was 27.5&#xa0;months (range 3—88). There was no significant change in creatinine due to IGTA. Primary efficacy of ablation was 94% (43/46 tumours). MWA had a lower primary efficacy than RFA (82% (14/17) vs 100% (28/28) respectively, (<i>p</i> = 0.02)). Larger median RCC diameter was associated with failed primary efficacy in the MWA group (3.8&#xa0;cm vs 2.4&#xa0;cm respectively, <i>p</i> = 0.035). OS was 97.4%, 88.5% and 88.5% at 1, 3 and 5&#xa0;years respectively. Local tumour progression free survival was 100%, 95.2% and 95.2% at 1, 3 and 5&#xa0;years respectively. Cancer specific survival at 5&#xa0;years was 100%.</p> Conclusions <p>IGTA provides an effective durable treatment option for patients with T1 RCCs. Primary efficacy was greater with RFA than MWA, although this may be influenced by the learning of curve for MWA during the study period. Primary efficacy failure in the MWA group is associated with greater median RCC diameters.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Image guided energy-based ablation of T1 renal cell cancer: a ten-year single centre experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月8日

查看全文
  • James P. C. Ryan,
  • Olwyn E. Lynch,
  • Barry B. McGuire,
  • Colin P. Cantwell

摘要

Purpose

Image-guided energy-based tumour ablation (IGTA) with radiofrequency ablation (RFA), microwave ablation (MWA) and cryotherapy are curative local therapies for T1 renal cell carcinoma (RCC). The aim of this study is to evaluate the oncological outcomes and survival after IGTA of T1 RCC in our unit over a 10-year period.

Methods

We retrospectively reviewed all patients with biopsy proven RCC who underwent IGTA of a T1 tumour between 1st March 2013 and 1st June 2023. Data collected included: patient demographics, tumour size and histology, pre and post procedure creatinine, ablation technique, complications, efficacy, disease free survival and overall survival (OS).

Results

Fifty IGTAs were performed on 46 RCC (mean diameter 2.6 cm) in 45 patients. Complications occurred in 8% of procedures (n = 4/50). Median clinical follow- up was 27.5 months (range 3—88). There was no significant change in creatinine due to IGTA. Primary efficacy of ablation was 94% (43/46 tumours). MWA had a lower primary efficacy than RFA (82% (14/17) vs 100% (28/28) respectively, (p = 0.02)). Larger median RCC diameter was associated with failed primary efficacy in the MWA group (3.8 cm vs 2.4 cm respectively, p = 0.035). OS was 97.4%, 88.5% and 88.5% at 1, 3 and 5 years respectively. Local tumour progression free survival was 100%, 95.2% and 95.2% at 1, 3 and 5 years respectively. Cancer specific survival at 5 years was 100%.

Conclusions

IGTA provides an effective durable treatment option for patients with T1 RCCs. Primary efficacy was greater with RFA than MWA, although this may be influenced by the learning of curve for MWA during the study period. Primary efficacy failure in the MWA group is associated with greater median RCC diameters.

Graphical Abstract